Patents Assigned to PANACEA BIOTEC LTD.
-
Patent number: 9133116Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).Type: GrantFiled: September 27, 2011Date of Patent: September 15, 2015Assignee: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Sudhir Kumar Sharma
-
Patent number: 8841306Abstract: The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H.Type: GrantFiled: November 18, 2009Date of Patent: September 23, 2014Assignee: Panacea Biotec Ltd.Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Sandeep Kanwar, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20140228303Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).Type: ApplicationFiled: June 13, 2012Publication date: August 14, 2014Applicant: Panacea Biotec LtdInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
-
Publication number: 20130280324Abstract: The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.Type: ApplicationFiled: September 15, 2011Publication date: October 24, 2013Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sarabjit Singh, Shivanand Puthli
-
Publication number: 20130253029Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).Type: ApplicationFiled: September 27, 2011Publication date: September 26, 2013Applicant: Panacea Biotec LtdInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Sudhir Kumar Sharma
-
Publication number: 20120165320Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.Type: ApplicationFiled: June 22, 2010Publication date: June 28, 2012Applicant: PANACEA BIOTEC LTD.Inventors: Rajseh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur, Sandeep Kanwar, Nishan Singh, Gurmeet Kaur Nanda, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20120010158Abstract: The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-?) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders.Type: ApplicationFiled: November 5, 2009Publication date: January 12, 2012Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Virendra Kumar Vinayak, Shweta Dubey, Shudhanand Prasad, Vijay Goel, Rahul Jain
-
Publication number: 20110268808Abstract: Orally deliverable dual-release pharmaceutical suspensions, having a first portion comprising an immediate release form of the active in the solution form or granules or suspended form in the vehicle/medium preferably in the solution form and a second portion comprising a sustained-release form of active in the form of microgranules/microparticles suspended in the immediate release fraction of the solulabilised active agent which comprise a core and at least one coat suitable for liquid dosage forms for the administration of the active ingredients, wherein the core comprises at least one active agent(s) or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; optionally at least one water insoluble, and optionally one or more pharmaceutically acceptable excipient(s); and at least one coat comprising at least one pH independent water-insoluble polymer(s) along with one or more pharmaceutically acceptable excipiType: ApplicationFiled: January 8, 2010Publication date: November 3, 2011Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sukhjeet Singh, Sanju Dhawan
-
Publication number: 20110245258Abstract: The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H.Type: ApplicationFiled: November 18, 2009Publication date: October 6, 2011Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Sandeep Kanwar, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20110130434Abstract: The invention relates to a modified release pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipient(s) wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of ramipril administered twice daily. The invention further relates to a modified release pharmaceutical composition comprising: an immediate release component comprising ramipril or pharmaceutically acceptable salts thereof and a modified release component comprising ramipril or pharmaceutically acceptable salts thereof. The invention further relates to the process for the preparation of modified release pharmaceutical composition of ramipril.Type: ApplicationFiled: July 28, 2009Publication date: June 2, 2011Applicant: Panacea Biotec Ltd.Inventors: Rajesh Jain, Sarabjit Singh
-
Publication number: 20110091536Abstract: Oral pharmaceutical compositions comprising dry extract of Euphorbia prostrata from about 0.1% to about 99% by weight wherein the effective average particle size of the dry extract of Euphorbia prostrata is not more than about 500 microns with pharmaceutically acceptable excipient(s) and process(s) for the preparation of such compositions useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease and the like are provided. Further, the pharmaceutical compositions of the present invention provides for the administration of a therapeutically and/or prophylactically effective amount of the Euphorbia prostrata wherein the compositions possess properties to control inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings.Type: ApplicationFiled: May 28, 2009Publication date: April 21, 2011Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sukhjeet Singh, Shilpa Bhasin
-
Publication number: 20100234288Abstract: Sustained release pharmaceutical composition comprising at least one poorly soluble active agent(s), at least one solubilizer, a release rate controlling polymer system consisting of an acid-soluble polymer and a pH-dependent polymer, and optionally other pharmaceutically acceptable excipients. The present invention also describes a process for preparation of such compositions and method of using such compositions. The sustained release compositions are useful in providing therapeutically effective levels of active agent(s) for extended periods of time.Type: ApplicationFiled: March 19, 2007Publication date: September 16, 2010Applicant: PANACEA BIOTEC LTDInventors: Rajesh Jain, Kour Chand Jindal, Sampath Kumar Devarajan
-
Publication number: 20100204333Abstract: Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.Type: ApplicationFiled: July 19, 2006Publication date: August 12, 2010Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh, Munish Talwar
-
Publication number: 20090317464Abstract: The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a higher bioavailability and improved pharmacokinetic profile as compared to a conventional bicalutamide composition.Type: ApplicationFiled: July 5, 2007Publication date: December 24, 2009Applicant: PANACEA BIOTEC LTD.Inventors: Amarjit Singh, Sarabjit Singh, Shivanand Puthli
-
Publication number: 20090258896Abstract: Novel compositions comprising a combination of at least one higher primary aliphatic alcohol preferably selected from those having 18 to 40 carbon atoms or mixtures thereof, at least one source of 5-hydroxytryptophan (5-HTP) optionally additionally comprising a source of caffeine and/or catechin-polyphenol and/or epigallocatechin gallate as active agents, either alone or in combination with other active agent(s), optionally with one or more excipient(s) are provided. Particularly, the invention relates to compositions and process for preparation of such compositions and method of use thereof for the management of obesity and associated disorders.Type: ApplicationFiled: May 9, 2007Publication date: October 15, 2009Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal
-
Publication number: 20090099154Abstract: Pharmaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, solvates, or salts thereof; preferably an antiviral active agent is provided. Also provided is a process of preparation of such composition and method of using them. The sustained release compositions of the present invention are able to deliver the active agent in a desired manner for an extended period of time.Type: ApplicationFiled: June 29, 2006Publication date: April 16, 2009Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh, Sanjay Boldhane
-
Publication number: 20090099151Abstract: Novel modified release pharmaceutical composition comprising at least one active agent(s); a polymer system in an amount less than about 80% w/w of the composition comprising at least two swellable pH independent polymers wherein at least one is hydrophilic; optionally other pharmaceutically acceptable excipients is provided. Process for preparation of such compositions and methods of using them is also provided. The compositions are formulated into suitable dosage forms that provide therapeutic concentrations of active agent for extended periods of time.Type: ApplicationFiled: June 29, 2006Publication date: April 16, 2009Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh, Sanjay Boldhane
-
Publication number: 20080261866Abstract: Pharmaceutical compositions comprising of glycosaminoglycan or salts thereof, preferably chondroitin or salts thereof, more preferably chondroitin sulphate, and nonsteroidal anti-inflammatory drug(s) or salts thereof, optionally with pharmaceutically acceptable excipient(s) are described. The compositions of the present invention provide gastrosparing effect in conditions where nonsteroidal anti-inflammatory drug(s) or their salts are used, particularly in mammals. Also provided are process for the manufacture of such novel compositions and method to minimize the nonsteroidal anti-inflammatory drug(s) induced gastric toxicity.Type: ApplicationFiled: January 19, 2005Publication date: October 23, 2008Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh
-
Publication number: 20080247962Abstract: A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from (24) to (39) carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or derivatives thereof, preferably statins, optionally with pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.Type: ApplicationFiled: January 19, 2005Publication date: October 9, 2008Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh
-
Controlled Release Pharmaceutical Composition Comprising An Acid-Insoluble And A Bioadhesive Polymer
Publication number: 20070219175Abstract: Rapidly disintegrating oral controlled release pharmaceutical compositions and process for preparation of such compositions are provided. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably amoxicillin either alone or in combination with other antibiotic(s). The controlled release compositions comprise at least one active ingredient, and a polymer system comprising of at least two polymers which retard the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in the alkaline contents of small intestine, optionally with other pharmaceutically acceptable excipients. The compositions provide therapeutically effective levels of the active ingredient for extended periods of time, and possess bioadhesive properties.Type: ApplicationFiled: January 5, 2005Publication date: September 20, 2007Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Jindal, Sukhjeet Singh